SG10201506264QA - Treatment of diabetes with pancreatic endocrine precursor cells - Google Patents

Treatment of diabetes with pancreatic endocrine precursor cells

Info

Publication number
SG10201506264QA
SG10201506264QA SG10201506264QA SG10201506264QA SG10201506264QA SG 10201506264Q A SG10201506264Q A SG 10201506264QA SG 10201506264Q A SG10201506264Q A SG 10201506264QA SG 10201506264Q A SG10201506264Q A SG 10201506264QA SG 10201506264Q A SG10201506264Q A SG 10201506264QA
Authority
SG
Singapore
Prior art keywords
diabetes
treatment
precursor cells
pancreatic endocrine
endocrine precursor
Prior art date
Application number
SG10201506264QA
Inventor
Jean Xu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG10201506264QA publication Critical patent/SG10201506264QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
SG10201506264QA 2010-08-12 2011-08-11 Treatment of diabetes with pancreatic endocrine precursor cells SG10201506264QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37310910P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
SG10201506264QA true SG10201506264QA (en) 2015-09-29

Family

ID=45564982

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013005921A SG187603A1 (en) 2010-08-12 2011-08-11 Treatment of diabetes with pancreatic endocrine precursor cells
SG10201506264QA SG10201506264QA (en) 2010-08-12 2011-08-11 Treatment of diabetes with pancreatic endocrine precursor cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013005921A SG187603A1 (en) 2010-08-12 2011-08-11 Treatment of diabetes with pancreatic endocrine precursor cells

Country Status (15)

Country Link
US (1) US20120039955A1 (en)
EP (2) EP3981415A1 (en)
JP (5) JP2013533319A (en)
KR (3) KR20180032674A (en)
CN (1) CN103052393B (en)
AR (1) AR082674A1 (en)
AU (1) AU2011289379A1 (en)
BR (1) BR112013003160A2 (en)
CA (1) CA2807158A1 (en)
DK (1) DK2603226T3 (en)
MX (1) MX2013001673A (en)
RU (2) RU2682719C2 (en)
SG (2) SG187603A1 (en)
WO (1) WO2012021698A2 (en)
ZA (1) ZA201301836B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140234963A1 (en) 2011-06-21 2014-08-21 Novo Nordisk A/S Efficient induction of definitive endoderm from pluripotent stem cells
RU2016100219A (en) 2013-06-11 2017-07-17 Президент Энд Феллоус Оф Гарвард Колледж SC-β CELLS AND COMPOSITIONS AND METHODS FOR THEIR CREATION
JP2017521089A (en) * 2014-05-14 2017-08-03 ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ アバーディーンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｏｕｒｔ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ａｂｅｒｄｅｅｎ Obtaining pancreatic endocrine cells
EP3143129A1 (en) * 2014-05-14 2017-03-22 The University Court of The University of Aberdeen Methods of obtaining islet cells
WO2016100930A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived b cells and methods of use thereof
EP3234110B1 (en) 2014-12-18 2024-02-28 President and Fellows of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED ß CELLS AND USES THEREOF
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
EP3268016B1 (en) 2015-03-11 2021-04-28 CCS Ventures Limited Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)
EP3537986A4 (en) * 2016-11-10 2020-06-03 ViaCyte, Inc. Pdx1 pancreatic endoderm cells in cell delivery devices and methods thereof
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2019099725A1 (en) 2017-11-15 2019-05-23 Semma Therapeutics, Inc. Islet cell manufacturing compositions and methods of use
WO2020033879A1 (en) 2018-08-10 2020-02-13 Semma Therapeutics, Inc. Stem cell derived islet differentiation
CA3139590C (en) 2019-05-31 2024-01-23 W. L. Gore & Associates, Inc. A biocompatible membrane composite
US20220234006A1 (en) 2019-05-31 2022-07-28 W. L. Gore & Associates, Inc. A biocompatible membrane composite
US20220233298A1 (en) 2019-05-31 2022-07-28 W. L. Gore & Associates, Inc. A biocompatible membrane composite
CN114401752B (en) 2019-05-31 2023-04-04 W.L.戈尔及同仁股份有限公司 Cell encapsulation device with controlled oxygen diffusion distance
KR102247950B1 (en) * 2019-10-16 2021-05-04 가톨릭대학교 산학협력단 Method for predicting risk of new onset diabetes after transplantation

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557264A (en) 1984-04-09 1985-12-10 Ethicon Inc. Surgical filament from polypropylene blended with polyethylene
US5863531A (en) 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5567612A (en) 1986-11-20 1996-10-22 Massachusetts Institute Of Technology Genitourinary cell-matrix structure for implantation into a human and a method of making
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6224912B1 (en) * 1996-04-03 2001-05-01 The Rogo Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
WO1999020740A2 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
CO4980885A1 (en) 1997-12-29 2000-11-27 Ortho Mcneil Pharm Inc TRIPHENYL PROPANAMIDE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATIONS AND METHODS FOR PREPARING SUCH A COMPOUND
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
US6326201B1 (en) * 1999-02-10 2001-12-04 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto
US6333029B1 (en) 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US6306424B1 (en) 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
AU7719300A (en) * 1999-09-27 2001-04-30 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US7439064B2 (en) 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US7793111B1 (en) 2000-09-28 2010-09-07 Intel Corporation Mechanism to handle events in a machine with isolated execution
JP4524072B2 (en) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
US6599323B2 (en) 2000-12-21 2003-07-29 Ethicon, Inc. Reinforced tissue implants and methods of manufacture and use
US20040121460A1 (en) * 2001-01-24 2004-06-24 Lumelsky Nadya L Differentiation of stem cells to pancreatic endocrine cells
US6656488B2 (en) 2001-04-11 2003-12-02 Ethicon Endo-Surgery, Inc. Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
PL374557A1 (en) * 2001-11-09 2005-10-31 Artecel Sciences, Inc. Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
IL162131A0 (en) 2001-12-07 2005-11-20 Geron Corp Islet cells from human embryonic stem cells
US20060003446A1 (en) 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
JP2005537803A (en) * 2002-09-06 2005-12-15 アムサイト インコーポレーティッド CD56 positive human adult pancreatic endocrine precursor cells
US20040062753A1 (en) 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
WO2005045001A2 (en) * 2003-02-14 2005-05-19 The Board Of Trustees Of The Leland Stanford Junior University Insulin-producing cells derived from stem cells
ITRM20030395A1 (en) 2003-08-12 2005-02-13 Istituto Naz Per Le Malattie Infettive Lazz CULTURE GROUND FOR MAINTENANCE, PROLIFERATION AND DIFFERENTIATION OF MAMMALIAN CELLS.
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
WO2005065354A2 (en) 2003-12-31 2005-07-21 The Burnham Institute Defined media for pluripotent stem cell culture
US20080241107A1 (en) 2004-01-23 2008-10-02 Copland Iii John A Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells
AU2005221079B2 (en) 2004-03-10 2010-07-22 Regents Of The University Of California Compositions and methods for growth of embryonic stem cells
JP5131833B2 (en) * 2005-10-05 2013-01-30 晃文 松山 Method for obtaining pancreatic endocrine cells from adipose tissue-derived cells
DK2650360T3 (en) * 2006-03-02 2019-10-07 Viacyte Inc Endocrine precursor cells, pancreatic hormone-expressing cells, and methods of preparation
JP5769965B2 (en) * 2007-07-31 2015-08-26 ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． Differentiation of human embryonic stem cells
CA3123528A1 (en) * 2007-11-27 2009-06-04 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
WO2010057039A2 (en) * 2008-11-14 2010-05-20 Cythera, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US11779311B2 (en) 2018-09-14 2023-10-10 Fujifilm Sonosite, Inc. Method and apparatus for performing spectral doppler imaging

Also Published As

Publication number Publication date
JP2019131564A (en) 2019-08-08
EP2603226A2 (en) 2013-06-19
ZA201301836B (en) 2018-12-19
US20120039955A1 (en) 2012-02-16
RU2016133754A (en) 2018-12-10
EP2603226A4 (en) 2014-01-15
DK2603226T3 (en) 2021-06-07
SG187603A1 (en) 2013-03-28
RU2016133754A3 (en) 2018-12-10
JP2017031163A (en) 2017-02-09
KR20190027969A (en) 2019-03-15
CN103052393A (en) 2013-04-17
JP2020196728A (en) 2020-12-10
EP3981415A1 (en) 2022-04-13
BR112013003160A2 (en) 2016-06-28
AU2011289379A1 (en) 2013-02-07
WO2012021698A2 (en) 2012-02-16
CA2807158A1 (en) 2012-02-16
AR082674A1 (en) 2012-12-26
RU2013110524A (en) 2014-09-20
JP7012128B2 (en) 2022-01-27
RU2682719C2 (en) 2019-03-21
WO2012021698A3 (en) 2012-05-10
EP2603226B1 (en) 2021-04-07
KR20130100122A (en) 2013-09-09
JP2013533319A (en) 2013-08-22
CN103052393B (en) 2017-11-14
MX2013001673A (en) 2013-03-25
KR20180032674A (en) 2018-03-30
JP2022058629A (en) 2022-04-12

Similar Documents

Publication Publication Date Title
ZA201301836B (en) Treatment of diabetes with pancreatic endocrine precursor cells
IL224451A (en) Method of producing pancreatic hormone-producing cells
EP2675459A4 (en) Compounds and methods of treating diabetes
ZA201304280B (en) Treatment of jak2-mediated conditions
IL222778A0 (en) Diabetes therapy
IL220889A0 (en) Methods of treating diabetes with dll4 antagonists
EP2717924A4 (en) Modulation of pancreatic beta cell proliferation
ZA201205425B (en) Treatment with vb-201
ZA201207973B (en) Treatment of gout
EP2601279A4 (en) Supertorrefaction of biomass into biocoal
IL223289A0 (en) Treatment of type 2 diabetes
PL2648737T3 (en) Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3
SG11201408717XA (en) Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
EP2649206A4 (en) Predicting and treating diabetic complications
HK1202819A1 (en) Treatment of type i and type ii diabetes i ii
HU0900178D0 (en) Stronger paper-pallet with use of simple geometrical structure
TWM401837U (en) Improved structure of solid state drive
TWM391169U (en) Improved structure of solid state drive
AU2010902914A0 (en) Treatment of diabetes
GB0904271D0 (en) Treatment of diabetes and metabolic syndrome
GB0910904D0 (en) Treatment of diabetes and metabolic syndrome
GB0912906D0 (en) Treatment of diabetes and metabolic syndrome
TWM401989U (en) Improved structure of feedstuff-feeding barrel
GB201115553D0 (en) Treatment of mast cell related disorder
ZA200907778B (en) Method of treating diabetes